A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).
Clinical trial NCT03355157 · COMPLETED
Trial details
- NCT number
- NCT03355157
- Sponsor
- GBG Forschungs GmbH
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-01
- Primary completion
- 2024-08-30
- Enrollment
- 130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.